In:
Science Translational Medicine, American Association for the Advancement of Science (AAAS), Vol. 15, No. 683 ( 2023-02-15)
Abstract:
Strategies to suppress innate and adaptive immune responses in inflammatory skin diseases such as atopic dermatitis and psoriasis are needed for patients with these chronic diseases. Here, Lavazais et al . comprehensively profiled an inhibitor of the kinase IRAK4, GLPG2534, as a therapeutic for inflammatory skin diseases. Because IRAK4 integrates signaling from multiple immune receptors, its inhibition with GLPG2534 should broadly suppress inflammation. The authors found that GLPG2534 treatment did indeed suppress inflammatory responses in both immune and non-immune cell types and dampened disease in mouse models of atopic dermatitis and psoriasis. Similar effects were observed in biopsies from patients with these diseases, supporting further clinical development of IRAK4 inhibitors in this therapeutic area. —CM
Type of Medium:
Online Resource
ISSN:
1946-6234
,
1946-6242
DOI:
10.1126/scitranslmed.abj3289
Language:
English
Publisher:
American Association for the Advancement of Science (AAAS)
Publication Date:
2023
Bookmarklink